Colliers International, a global real estate services and investment management company with a special focus on the life sciences sector, has released its new Philadelphia Life Sciences Perspectives Report.
The report showcases Greater Philadelphia’s transformative life sciences sector, recognizing our attractive and competitive assets that set our region apart from other metropolitan areas.
Collier highlights Big Pharma, University and Institutional Research, and the Commercial R&D Inventory throughout our 11-county region, including University of Pennsylvania Perelman School of Medicine, Johnson and Johnson, and Incyte. Collectively, the three sectors make up 22.4 million square feet of life science real estate in the region. Pharmaceutical campuses in the region create more than 19,000 jobs, while consistently retaining and advancing talent.
The report features Amicus Therapeutics, a biotech company that recently relocated to Philadelphia. Amicus’s CEO, John Crowley shared why the company chose to locate and operate in our region, “Philadelphia became the clear choice as a burgeoning hub for medical breakthroughs… the area also provides a tremendous opportunity to advance our commitment to gene therapies.”
Our region has seen a rise in biotech companies throughout the county and around the world that are relocating or expanding operations here.
Select recently released our latest report called Business Is Greater Here, which showcases Greater Philadelphia’s growing workforce, innovation & entrepreneurship, highly-ranked life sciences, value & opportunity, transformations, energy sector, access to market, expanding technology industry, and competitive, low-cost livability all throughout our 11-county region.